Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria

Alzheimer's and Dementia

Volumn 9, Issue 5, 2013, Pages 594-601

  Carrillo, Maria C ^a   Dean, Robert A ^b   Nicolas, François ^c   Miller, David S ^d   Berman, Robert ^e   Khachaturian, Zaven ^f   Bain, Lisa J ^g   Schindler, Rachel ^h   Knopman, David ⁱ  

^a ALZHEIMER'S ASSOCIATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c General Electric   (United Kingdom)

^d Dementia and Geriatric Psychiatry Bracket   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f PAD2020   (United States)

^g Pfizer ^*

^h PFIZER INC   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Dementia; Diagnostic criteria

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; GANTENERUMAB; MONOCLONAL ANTIBODY; PRESENILIN 1; SOLANEZUMAB;

ALGORITHM; ALZHEIMER DISEASE; APHASIA; BEHAVIOR DISORDER; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; DEPTH PERCEPTION; DIAGNOSTIC ACCURACY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FREE AND CUED SELECTIVE REMINDING TEST; HUMAN; INTERNATIONAL COOPERATION; LANGUAGE DISABILITY; LEARNING DISORDER; LUMBAR PUNCTURE; MEDICAL SOCIETY; MEDICAL TERMINOLOGY; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECALL; REVIEW; VALIDATION PROCESS;

ALZHEIMER'S DISEASE; BIOMARKERS; DEMENTIA; DIAGNOSTIC CRITERIA;

ALZHEIMER DISEASE; HUMANS; NATIONAL INSTITUTE ON AGING (U.S.); UNITED STATES;

EID: 84883528928     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.05.1762     Document Type: Article

References (30)

1. C.R. Jack Jr., M. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo Introduction to revised criteria for the diagnosis of Alzheimer's disease: National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 257 262
2. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746 (Pubitemid 47058377)
3. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944 (Pubitemid 14076461)
4. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 263 269
5. M.S. Albert, S.T. Dekosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
6. J.A. Schneider, Z. Arvanitakis, S.E. Leurgans, and D.A. Bennett The neuropathology of probable Alzheimer disease and mild cognitive impairment Ann Neurol 66 2009 200 208
7. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup Alzheimers Dement 7 2011 280 292
8. M.C. Carrillo, H.R. Brashear, V. Logovinsky, J.M. Ryan, H.H. Feldman, and E.R. Siemers Can we prevent Alzheimer's disease? Secondary " prevention" trials in Alzheimer's disease Alzheimers Dement 9 2013 123 131.e1
9. R.J. Bateman, C. Xiong, T.L.S. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network N Engl J Med 367 2012 795 804
10. I.A. van Rossum, S. Vos, R. Handels, and P.J. Visser Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design J Alzheimers Dis 20 2010 881 891
11. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
12. M. Wagner, S. Wolf, F.M. Reischies, M. Daerr, S. Wolfsgruber, and F. Jessen Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease Neurology 78 2012 379 386
13. S. Auriacombe, C. Helmer, H. Amieva, C. Berr, B. Dubois, and J.F. Dartigues Validity of the Free and Cued Selective Reminding Test in predicting dementia: the 3C study Neurology 74 2010 1760 1767
14. P.J. Visser, S. Vos, I. van Rossum, and P. Scheltens Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease Alzheimers Dement 8 2012 560 563
15. D.M. Rentz, R.E. Amariglio, J.A. Becker, M. Frey, L.E. Olson, and K. Frishe Face-name associative memory performance is related to amyloid burden in normal elderly Neuropsychologia 49 2011 2776 2783
16. M. Sarazin, C. Berr, J. De Rotrou, C. Fabrigoule, F. Pasquier, and S. Legrain Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study Neurology 69 2007 1859 1867 (Pubitemid 350071147)
17. M.I. Kester, L. Boelaarts, F.H. Bouwman, R.L. Vogels, E.R. Groot, and E.J. van Elk Diagnostic impact of CSF biomarkers in a local hospital memory clinic Dement Geriatr Cogn Disord 29 2010 491 497
18. N.S. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 2012 47 54
19. I.A. van Rossum, P.J. Visser, D.L. Knol, W.M. van der Flier, C.E. Teunissen, and F. Barkhof Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease J Alzheimers Dis 29 2012 319 327
20. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
21. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
22. S.M. Landau, M.A. Mintun, A.D. Joshi, R.A. Koeppe, R.C. Petersen, and P.S. Aisen Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 72 2012 578 586
23. S. Negash, S. Xie, C. Davatzikos, C.M. Clark, J.Q. Trojanowski, and L.M. Shaw Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology Alzheimers Dement 9 2013 e89 e95
24. D.M. Rentz, J.J. Locascio, J.A. Becker, E.K. Moran, E. Eng, and R.L. Buckner Cognition, reserve, and amyloid deposition in normal aging Ann Neurol 67 2010 353 364
25. N. Acosta-Baena, D. Sepulveda-Falla, C.M. Lopera-Gomez, M.C. Jaramillo-Elorza, S. Moreno, and D.C. Aguirre-Acevedo Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study Lancet Neurol 10 2011 213 220
26. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, and M.C. Carrillo National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
27. D.A. Evans, F. Grodstein, D. Loewenstein, J. Kaye, and S. Weintraub Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 2 Alzheimers Dement 7 2011 110 123
28. Eli Lilly and Company. Lilly announces detailed results of the Phase 3 Solanezumab EXPEDITION studies following a presentation of the independent analyses by the Alzheimer's Cooperative Study (ADCS). Press release October 8, 2012.
29. Pfizer Inc. Pfizer announces topline results of first of four studies in Bapineuzumab phase 3 program. Press release July 23, 2012.
30. Z.S. Khachaturian Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 253 256